IBA 
Tab C - Page 15 
a £ C*o# 
C 0*A Corportu an 
Wc* A * * J+$ * t 
(Ucnte Scftmfpx 
OtnMCI MnMuM 
Z*c r *frf 
Ho** G Sc^oet>*« 
0 0 S««n« 4 Compter 
Tr+mvrwf 
*cft**L U u »M y 
^T\*rm*oa W»c 
j G/at* 8< f»n 
AA*d CorpcyMon 
Hugn A 0'Asyjr*o« 
Coroorvfcoft 
JOM « Nor«« 
Pt u tpt Pmirxjtmum Company 
Oav«*J 
Agng*o**C 4 Cotoouon 
Otorg* 6 «»crvT\*ny» 
A mg«n 
Uprti 8 Stu f f y 
B«og«n 
«oo#fi A S**n«on 
G«<fn**cn. inc 
L w*oo 
O»mon B«o*ac« 
Industrial Biotechnology Association 
2115 East Jeltofson Street 
Rockville. Maryland 20852 
Telephone: (301 ) 984-9598 
Harvey 1. Price 
Executive Director 
May 14, 1985 
Dr. William J. GarCland 
Office of Recombinant DNA 
Activities 
Building 31, Room 3B10 
National Institute of Health 
Bethesda, Maryland 20205 
Re: Environmental Assessment and 
Finding of No Significant 
Impact (January 21, 1985) 
Dear Dr. Gartland: 
The Industrial Biotechnology Association would like to express its 
agreement with the conclusion of NIH's environmental assessment in the 
ice-nucleation experiment case, that the modified field test proposal would 
have no significant environmental impact. We believe that the formal 
assessment makes clear that NIH's conclusion is supported by careful 
thought and abundant scientific evidence. While mindful of other public 
interests, the interest of encouraging such promising biotechnology 
research argues that NIH's substantial and conscientious effort to date 
should now be judged as fully adequate. 
We also concur in NIH's earlier conclusion that a programmatic 
environmental impact statement would not be appropriate in connection with 
environmental release approvals at this time, for the facts and reasons set 
out in item III of the Federal Register notice. 
Sincerely , 
[280] 
